Skip to content
Triangle logo TriangleGet started
← Study library

NCT00096161 · REGISTRY CONDITION SEARCH

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2020-01-31

This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant. Giving pentostatin and an infusion of the donor's T cells (donor lymphocyte infusion) after a donor stem cell transplant may stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before donor lymphocyte infusion may stop this from happening.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage Patients With an Increase of at Least 10 Percentage Points in Donor T-cell Chimerism

→

outcome · POSTED

Incidence of Grade IV Acute GVHD

→

outcome · POSTED

Incidence of GVHD

→

outcome · POSTED

Incidence of Infections

→

outcome · POSTED

Incidence of Relapse/Progression

→

outcome · POSTED

Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients having received a preceding allogeneic transplantation from either a human leukocyte antigen (HLA)-matched related or unrelated donor are eligible for this protocol * Related donor: HLA genotypically identical at least at one haplotype and may be phenotypically or genotypically identical at the allele level at HLA A, B, C, DRB1, and DQB1 * Unrelated donor who are prospectively: * Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR * Only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing * Patients with less than 50% donor CD3 peripheral blood chimerism on two separate, consecutive evaluations; the two evaluations must be at least 14 days apart OR patients with absolute decreases of donor CD3 peripheral blood chimerism of \>= 20% if the second test shows \< 50% donor CD3 cells; the two evaluations must be at least 14 days apart * Patients with evidence of disease are only eligible if the disease is stable (or persistent) in comparison to the status prior to transplantation * Patients must be tapered off systemic steroids to a dosage of less than or equal to 0.25 mg/kg/day * Patients must have persistent donor CD3 cells (\>= 5% donor CD3 cells by a deoxyribonucleic acid \[DNA\]-based assay that compares the profile of amplified fragment length polymorphisms \[ampFLP\] \[or fluorescent in situ hybridization (FISH) studies or variable number of tandem repeats (VNTR)\]) * DONOR: Alternatively to a fresh unmodified leukapheresis product, previously collected cryopreserved peripheral blood stem cells (PBSC) after mobilization with G-CSF or cryopreserved unmodified leukapheresis product from the original donor can be used; if cryopreserved product is not available, the following criteria apply for the DLI product: * DONOR: Original donor of hematopoietic cell transplantation * DONOR: Donor must give consent to leukapheresis * DONOR: Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral or subclavian) * DONOR: Donor must be medically fit to undergo the apheresis procedure (institutional guidelines for apheresis) Exclusion Criteria: * Current grade II to IV acute GVHD or extensive chronic GVHD * Karnofsky score \< 50% * Pediatric criteria * Lansky play-performance score \< 40 * Evidence of relapse or progression of disease after transplantation * Prior recipient of cord blood * DONOR: Donors who are not suitable for medical reasons to donate peripheral blood mononuclear cells (PBMC) by continuous centrifugation according to the criteria of the American Association of Blood Banks (AABB) * DONOR: Pregnancy * DONOR: Human immunodeficiency virus (HIV) or human T-lymphotrophic virus (HTLV) infection * DONOR: Recent immunization may require a delay
healthy Volunteers
false
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Group I (pentostatin, DLI): Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart. Group II (pentostatin, DLI, mycophenolate mofetil, cyclosporine): Patients receive treatment as in group I. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD.
    intervention Names
    1. Drug: Cyclosporine
    2. Drug: Mycophenolate Mofetil
    3. Drug: Pentostatin
    4. Biological: Therapeutic Allogeneic Lymphocytes
    label
    pentostatin, DLI, mycophenolate mofetil, cyclosporine
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. pentostatin, DLI, mycophenolate mofetil, cyclosporine
    description
    Given PO
    name
    Cyclosporine
    other Names
    1. 27-400
    2. Ciclosporin
    3. CsA
    4. Cyclosporin
    5. Cyclosporin A
    6. Neoral
    7. OL 27-400
    8. Sandimmun
    9. Sandimmune
    10. SangCya
    type
    DRUG
  2. arm Group Labels
    1. pentostatin, DLI, mycophenolate mofetil, cyclosporine
    description
    Given PO
    name
    Mycophenolate Mofetil
    other Names
    1. Cellcept
    2. MMF
    type
    DRUG
  3. arm Group Labels
    1. pentostatin, DLI, mycophenolate mofetil, cyclosporine
    description
    Given IV
    name
    Pentostatin
    other Names
    1. (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7, 8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
    2. 2'-Deoxycoformycin
    3. CI-825
    4. Co-Vidarabine
    5. Covidarabine
    6. DCF
    7. Deoxycoformycin
    8. Nipent
    9. PD-81565
    10. Pentostatine
    type
    DRUG
  4. arm Group Labels
    1. pentostatin, DLI, mycophenolate mofetil, cyclosporine
    description
    Given IV
    name
    Therapeutic Allogeneic Lymphocytes
    other Names
    1. Allogeneic Lymphocytes
    type
    BIOLOGICAL
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
36
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    A regimen will be considered successful if 20 patients are enrolled, at least 13 demonstrate improved chimerism. If fewer than 5 patients have shown improvement in chimerism then it can be at least 75% confident that the true rate of improvement is less than 0.53. Enrollment to the regimen will stop and the next regimen will be opened. Enrollment to a regimen may also be stopped at any time it becomes impossible to achieve 5 of 10 or 13 of 20 successful improvements. "Chimerism" in hematopoietic cell transplant derives from this idea of a "mixed" entity, referring to someone who has received a transplant of genetically different tissue. A test for chimerism after a hematopoietic cell transplant involves identifying the genetic profiles of the recipient and of the donor and then evaluating the extent of mixture in the recipient's blood cells or marrow cells.
    measure
    Percentage Patients With an Increase of at Least 10 Percentage Points in Donor T-cell Chimerism
    time Frame
    From the time of enrollment maintained to day 56 after the last DLI, up to Day 112
  2. description
    Clinical Stage of acute GVHD according to Organ System Skin: 1. \- Maculopapular rash \<25% of body surface 2. \- Maculopapular rash 25-50% of body surface 3. \- Maculopapular rash \>50% body surface area or generalized erythroderma 4. \- Generalized erythroderma with bullous formation and desquamation Liver: 1. \- Bilirubin 2-3 mg/dl 2. \- Bilirubin 3.1-6 mg/dl 3. \- Bilirubin 6.1-15 mg/dl 4. \- Bilirubin \>15 mg/dl Gut: 1. \- \>500-1000 mL diarrhea per day or (nausea, anorexia or vomiting with biopsy (EGD) confirmation of upper GI GVHD 2. \- \>1000 -1500 mL diarrhea per day 3. \- \>1500 mL diarrhea per day 4. \- \>1500 mL diarrhea per day plus severe abdominal pain with or without ileus Overall Clinical Grading of Severity of acute GVHD Grade IV: 0-4 Skin, 2-4 Liver, and/or 2-4 GI
    measure
    Incidence of Grade IV Acute GVHD
    time Frame
    Within 100 days after the last DLI
secondary Outcomes
  1. description
    Percentage patients with acute or chronic GVHD. The diagnosis of chronic GVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.
    measure
    Incidence of GVHD
    time Frame
    1 year after DLI
  2. measure
    Incidence of Infections
    time Frame
    100 days after DLI
  3. description
    CML Acquisition of a new cytogenetic abnormality and/or development of accelerated phase or blast crisis. Criteria for accelerated phase: unexplained fever \>38.3° C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, BM blasts and promyelocytes \>20%. AML, ALL, CMML \>30% BM blasts w/ deteriorating performance status, or worsening of anemia, neutropenia, or thrombocytopenia. CLL Progressive disease: ≥1 of: physical exam/imaging studies (nodes, liver, and/or spleen) ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation. NHL \>25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions. MM ≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ tx; or definite increase in the size/number of plasmacytomas or lytic bone lesions.
    measure
    Incidence of Relapse/Progression
    time Frame
    1 year after DLI
  4. description
    Percentage patients surviving.
    measure
    Survival
    time Frame
    1 year after DLI
Full study description
brief Summary
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant. Giving pentostatin and an infusion of the donor's T cells (donor lymphocyte infusion) after a donor stem cell transplant may stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before donor lymphocyte infusion may stop this from happening.
detailed Description
PRIMARY OBJECTIVES: I. To assess the safety and efficacy of the combined use of pentostatin and donor lymphocyte infusion (DLI) in patients with low or falling donor T-cell chimerism to prevent graft rejection after transplantation both from matched related donors (MRDs) or unrelated donors (URDs). SECONDARY OBJECTIVES: I. To determine the incidence of graft-versus-host disease (GvHD) infections and disease response, if persistent disease is present. OUTLINE: This is a dose-escalation study of donor lymphocyte infusion. GROUP I: Patients receive pentostatin intravenously (IV) over 20-30 minutes on day -2 and DLI over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same cluster of differentiation (CD)3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart. GROUP II (initiated if patients in group I do not achieve sustained engraftment and improved chimerism): Patients receive treatment as in group I. Patients also receive cyclosporine orally (PO) twice daily (BID) on days -3 to 56 and mycophenolate mofetil PO once daily (QD) on days 0 to 27. Treatment continues in the absence of GvHD. After completion of study treatment, patients are followed up every 6 months for 2 years and then annually thereafter.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-7d443acc6eaddada9d53
      requested nct id
      NCT00096161
      primary nct id
      NCT00096161
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      bb5fa2a8b5e288392556c2d3c429f4ee4dcae0948aa36da6401c9cddb6c26b26
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-7d443acc6eaddada9d53
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00096161
      occurrences
      1. context exact
        NCT00096161
        end
        11
        exact text
        NCT00096161
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/582/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      fef107b36bd1ba2c21e1b53cd28d45047545fecca87d502f96ee3312a5fe766a

    Preserved source evidence · Not medical advice